The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome

Basit Öğe Kaydı
dc.authoridBicer, Cemile/0000-0001-7937-4475|Kaygusuz, Ikbal/0000-0002-5635-505X;
dc.contributor.authorCarlioglu, Ayse
dc.contributor.authorKaygusuz, Ikbal
dc.contributor.authorKarakurt, Feridun
dc.contributor.authorGumus, Ilknur Inegol
dc.contributor.authorUysal, Aysel
dc.contributor.authorKasapoglu, Benan
dc.contributor.authorArmutcu, Ferah
dc.date.accessioned2025-10-24T18:08:48Z
dc.date.available2025-10-24T18:08:48Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractPurpose To evaluate the platelet activating factor acetyl hydrolyze (PAF-AH), oxidized low-density lipoprotein (ox-LDL), paraoxonase 1 (PON1), arylesterase (ARE) levels and the effects of metformin and Diane-35 (ethinyl oestradiol + cyproterone acetate) therapies on these parameters and to determine the PON1 polymorphisms among PCOS patients. Methods Ninety patients with PCOS, age 30, and body mass index-matched healthy controls were included in the study. Patients were divided into three groups: metformin treatment, Diane-35 treatment and no medication groups. The treatment with metformin or Diane-35 was continued for 6 months and all subjects were evaluated with clinical and biochemical parameters 6 months later. One-way Anova test, t test and non-parametric Mann-Whitney U tests were used for statistical analysis. Results PAF-AH and ox-LDL levels were statistically significantly higher in untreated PCOS patients than controls, and they were statistically significantly lower in patients treated with metformin or Diane-35 than untreated PCOS patients. In contrast, there were lower PON1 (not statistically significant) and ARE (statistically significant) levels in untreated PCOS patients than the control group and they significantly increased after metformin and Diane-35 treatments. In PCOS patients serum PON1 levels for QQ, QR and RR phenotypes were statistically significantly lower than the control group. Conclusion In patients with PCOS, proatherogenic markers increase. The treatment of PCOS with metformin or Diane-35 had positive effects on lipid profile, increased PON1 level, which is a protector from atherosclerosis and decreased the proatherogenic PAF-AH and ox-LDL levels.
dc.description.sponsorshipFatih University Foundation
dc.description.sponsorshipThis study was supported by Fatih University Foundation.
dc.identifier.doi10.1007/s00404-014-3275-8
dc.identifier.endpage935
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue5
dc.identifier.pmid24840107
dc.identifier.scopus2-s2.0-84927566203
dc.identifier.scopusqualityQ2
dc.identifier.startpage929
dc.identifier.urihttps://doi.org/10.1007/s00404-014-3275-8
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3308
dc.identifier.volume290
dc.identifier.wosWOS:000343651400017
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelberg
dc.relation.ispartofArchives Of Gynecology And Obstetrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectPolycystic ovary syndrome; Platelet activating factor acetyl hydrolyze; Oxidized LDL; Paraoxonase1; Paraoxonase1 phenotypes; Arylesterase
dc.titleThe platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu